



07 675105

BD1 CIP FWC II

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Sherie L. Morrison, et al.
Serial No. :
Filed :
For : CHIMERIC RECEPTORS BY DNA SPLICING
AND EXPRESSION
Group :
Examiner :

New York, New York
March 22, 1991

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Applicants have filed a continuation of
application serial no. 07/441,189 and now request amendment
of the application.

IN THE TITLE OF THE INVENTION

Before "RECEPTORS" delete --CHIMERIC--.

IN THE CLAIMS

Kindly amend the claims as follows:

39. A method for producing a receptor having two-
subunits, which comprises:

transfecting a mammalian cell with a DNA sequence
coding for one of the subunits of the receptor;

transfecting the cell with a second DNA sequence
coding for another of the subunits of the receptor;

maintaining the cell in a nutrient medium, whereby
the cell expresses the DNA sequences and the resultant
subunits are intracellularly bound together to form a
receptor.

ST
Sault
K, 1

101
Centel

40. A method as recited in claim 39 wherein the cell is transfected via protoplast fusion.

41. A method as recited in claim 39 wherein the cell is transfected via calcium phosphate precipitation.

42. A method as recited in claim 39 wherein the cell is a lymphoid cell.

43. A method as recited in claim 42 wherein the cell is a myeloma cell.

44. A method as recited in claim 43 wherein the cell is a murine myeloma cell.

Scrub
K2

45. A method as recited in claim 43 wherein the cell does not produce any endogenous immunoglobulin chains.

K1

46. A method as recited in claim 45 wherein the cell is a murine P₃ cell.

47. A method as recited in claim 43 wherein the cell endogenously produces only an immunoglobulin light chain or an immunoglobulin heavy chain.

K2

48. A method as recited in claim 47 wherein the cell is a murine J558L cell.

49. A receptor produced by the method of claim 39.

Scrub
K3

50. A receptor as recited in claim 49 comprising a molecule selected from the following group consisting of major histocompatibility complex class I, major

101
Control
Sub E37
cond.

major histocompatibility complex class I, major histocompatibility complex class II, antibody, T cell receptor and CD8.

51. A receptor as recited in claim 49 wherein the receptor is a chimeric antibody having a variable region substantially the same as that found in a first mammalian source and having a constant region substantially the same as that found in a second mammalian source.


Please cancel claims 14 - 38.

REMARKS

Applicants have added new claims 39 - 51. These claims are directed to a method for producing a receptor having two subunits and to the product of that method. These claims do not constitute new matter.

Applicants are preparing and will promptly file with the office a Supplemental Preliminary Amendment setting forth the bases for patentability of these claims over prior art which has been cited in the prior applications.

Respectfully submitted,


Edward F. Mallowney (Reg. No. 27,459)
Vicki S. Veenker (Reg. No. 34,269)